Omega-3s in Cardiovascular Prevention: What the Evidence Says
A pragmatic synthesis of where omega-3 fatty acid supplementation sits in cardiovascular prevention after REDUCE-IT, STRENGTH, and the secondary-prevention meta-analyses.
- Published
- 28 Apr 2026
- Read time
- 3 min read
A decade ago, omega-3 supplementation was being marketed to almost every patient with a vascular risk factor. The current evidence base is more nuanced: a clear benefit in a defined niche (high-dose pure EPA in established or high-risk atherosclerotic disease with hypertriglyceridaemia), no benefit in general primary prevention, and a real signal of harm (atrial fibrillation) at high doses.
The big trials
REDUCE-IT (2019) — icosapent ethyl
8179 patients with established CVD or diabetes plus risk factors, on statin, with TG 1.5-5.6 mmol/L (135-499 mg/dL). Randomised to icosapent ethyl 4 g/day (pure EPA) vs. mineral-oil placebo.
- 25% relative reduction in the composite of CV death, MI, stroke, coronary revascularisation, or unstable angina (HR 0.75, 95% CI 0.68-0.83).
- Number needed to treat ≈ 21 over a median 4.9 years.
- Statistically significant increase in atrial fibrillation (5.3% vs 3.9%) and bleeding (2.7% vs 2.1%).
The placebo (mineral oil) raised LDL by 10% and CRP, raising questions about whether some of the effect is "placebo harm" rather than EPA benefit. Most expert reviewers conclude the effect is too large to be entirely placebo-driven.
STRENGTH (2020) — mixed EPA/DHA
13 078 patients at high cardiovascular risk with hypertriglyceridaemia. Randomised to omega-3 carboxylic acid 4 g/day (mixed EPA + DHA) vs. corn oil placebo. Stopped early for futility.
- No difference in the primary composite endpoint.
- Higher incidence of atrial fibrillation in the omega-3 arm.
Evidence
REDUCE-IT and STRENGTH used different formulations (pure EPA vs. mixed EPA/DHA), different doses, and different placebos. The contrast suggests benefit is specific to high-dose pure EPA in a hypertriglyceridaemic, high-risk population — not a general "fish oil is good" finding.
General population — Aung meta-analysis (2018)
10 trials, 77 917 participants, primary and secondary prevention. No significant reduction in coronary heart disease death, non-fatal MI, or any major vascular event with omega-3 supplementation in this population.
The AF signal
A 2021 patient-level meta-analysis combining REDUCE-IT, STRENGTH, and others found a ~1.4× higher incidence of atrial fibrillation with omega-3 supplements at doses ≥1 g/day. The risk increases with higher doses. Anyone considering high-dose omega-3 for vascular prevention needs to weigh this — and have a baseline ECG.
Red flag
Avoid high-dose omega-3 in patients with paroxysmal AF, recent ablation, or those on anticoagulation where additional bleeding risk is unwelcome.
Practical recommendations
| Patient | Recommendation |
|---|---|
| Established ASCVD, on statin, TG 1.5-5.6 mmol/L | Consider icosapent ethyl 2 g BD (NICE TA805 in the UK for similar indication) |
| Established ASCVD, normal TGs | No clear role for omega-3 supplementation |
| Primary prevention, no risk factors | No role |
| Patient asks about over-the-counter fish oil | Reasonable food (oily fish 2× week); no clear benefit from low-dose supplements |
| Paroxysmal AF | Avoid high-dose omega-3 supplementation |
Don't confuse with prescription
Over-the-counter fish oil supplements are heterogeneous in EPA and DHA content, often combined, and dose-poor. The REDUCE-IT result applies to a specific, pharmaceutical-grade, pure EPA preparation, not to off-the-shelf supplements.
Clinical pearl
A patient on aspirin, a P2Y12 inhibitor, an anticoagulant, and 4 g of high-dose omega-3 has a meaningful cumulative bleeding risk. Review the full antithrombotic and supplement landscape, not just the prescription chart.
Key points
- High-dose pure EPA (icosapent ethyl 4 g/day) reduces MACE in statin-treated patients with established ASCVD and hypertriglyceridaemia.
- Mixed EPA/DHA preparations have not shown the same benefit.
- Omega-3 supplementation in primary prevention has no evidence base.
- All omega-3 supplementation increases AF risk; weigh this in patients with arrhythmia history.
References
- [1]Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. Link
- [2]Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280. Link
- [3]Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials. JAMA Cardiol. 2018;3(3):225-234. Link
About the author
Dr. Imani OkoroVerifiedVerified medical practitioner
MBBS, MRCP, PhD
Consultant cardiologist with a research interest in heart failure pharmacotherapy and remote monitoring. Edits the cardiology stream for MedSchool.
More in Cardiology
Managing Acute Decompensated Heart Failure on the Ward
A practical ward-level framework for the patient with acute decompensated heart failure — assessment, diuresis, and the early decisions that matter most.
Remote Ischaemic Preconditioning: A Clinical Evidence Update
A decade after promising mechanistic and pilot data, where does remote ischaemic preconditioning actually stand in cardiac and non-cardiac surgery?
Heart Failure Pharmacotherapy: The Four Pillars in Practice
A practical summary of guideline-directed medical therapy for HFrEF — the four pillars, how to initiate, and what order to titrate when the patient is in clinic.